ACADIA Pharmaceuticals Inc. reported $1.14B of revenue over the trailing twelve months, +12% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.14B (to Q2 2026). Net income: $380M, trailing twelve months to Q2 2026. Free cash flow: $146M, trailing twelve months to Q2 2026. Operating margin: 7.4%, trailing twelve months to Q2 2026.

ACADACADIA Pharmaceuticals Inc.

Healthcare

$19.78-19% 1Y

$19.78

$19.5752 weeks$30.58

ACAD as reported

ACADIA Pharmaceuticals Inc. reported $1.14B of revenue over the trailing twelve months, +12% on the year before. 10 reported series are charted on this page, each one as filed.

$1.14B

Revenue, trailing twelve months · to Q2 2026 · +12% against the twelve months before

Net income: $380M
Net income · +71% year on year · trailing twelve months to Q2 2026
Free cash flow: $146M
Free cash flow · −22% year on year · trailing twelve months to Q2 2026
Operating margin: 7.4%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ACAD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.14B	+12%	Q2 2026
Net income	$380M	+71%	Q2 2026
EPS	$2.23	+68%	Q2 2026
Gross margin	91%	n/a	Q2 2026
Operating margin	7.4%	n/a	Q2 2026
Net margin	33%	n/a	Q2 2026
ROE	30%	n/a	Q2 2026
ROA	22%	n/a	Q2 2026
Free cash flow	$146M	−22%	Q2 2026
P/E	8.87	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.